Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2015

Schedule of stock-based compensation expense related to all of the entity's share-based awards

Total stock-based compensation expense related to all of our share-based payments that we recognized for the three and six months ended June 30, 2015 and 2014 were as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2015		2014		2015		2014
Research and development	$	1,056	$	1,189	$	2,216	$	2,503
General and administrative	853		943		1,747		1,993

Total stock-based compensation expense	$	1,909	$	2,132	$	3,963	$	4,496

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2015		2014		2015		2014
Risk-free interest rate	1.9	%	2.2	%	1.8	%	2.1	%
Expected term (in years)	7.0		6.7		6.5		6.5
Dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	66.9	%	76.9	%	65.1	%	75.3	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan

	Six Months Ended
	June 30,
	2015		2014
Risk-free interest rate	0.6	%	0.3	%
Expected term (in years)	1.5		1.7
Dividend yield	0.0	%	0.0	%
Expected volatility	61.2	%	66.0	%